CO2017010510A2 - Tableta de ribociclib - Google Patents

Tableta de ribociclib

Info

Publication number
CO2017010510A2
CO2017010510A2 CONC2017/0010510A CO2017010510A CO2017010510A2 CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2 CO 2017010510 A CO2017010510 A CO 2017010510A CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2
Authority
CO
Colombia
Prior art keywords
ribociclib
tablet
coating
present disclosure
coated
Prior art date
Application number
CONC2017/0010510A
Other languages
English (en)
Spanish (es)
Inventor
Bindhumadhavan Gururajan
Arnaud Grandeury
Rui Costa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017010510(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO2017010510A2 publication Critical patent/CO2017010510A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2017/0010510A 2015-04-16 2017-10-13 Tableta de ribociclib CO2017010510A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
CO2017010510A2 true CO2017010510A2 (es) 2018-03-20

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0010510A CO2017010510A2 (es) 2015-04-16 2017-10-13 Tableta de ribociclib

Country Status (29)

Country Link
US (6) US10799506B2 (cg-RX-API-DMAC7.html)
EP (3) EP4620458A3 (cg-RX-API-DMAC7.html)
JP (1) JP2018514523A (cg-RX-API-DMAC7.html)
KR (2) KR20250009572A (cg-RX-API-DMAC7.html)
CN (2) CN107530292B (cg-RX-API-DMAC7.html)
AR (1) AR104257A1 (cg-RX-API-DMAC7.html)
AU (5) AU2016248017A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017021283A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982425C (cg-RX-API-DMAC7.html)
CL (1) CL2017002593A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017010510A2 (cg-RX-API-DMAC7.html)
DK (1) DK3283058T3 (cg-RX-API-DMAC7.html)
EA (1) EA201792290A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17075052A (cg-RX-API-DMAC7.html)
ES (1) ES2938261T3 (cg-RX-API-DMAC7.html)
FI (1) FI3283058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230053T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061213T2 (cg-RX-API-DMAC7.html)
IL (1) IL254818A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013350A (cg-RX-API-DMAC7.html)
PE (1) PE20180035A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501820A1 (cg-RX-API-DMAC7.html)
PL (1) PL3283058T3 (cg-RX-API-DMAC7.html)
PT (1) PT3283058T (cg-RX-API-DMAC7.html)
SG (1) SG11201708084PA (cg-RX-API-DMAC7.html)
SI (1) SI3283058T1 (cg-RX-API-DMAC7.html)
TN (1) TN2017000422A1 (cg-RX-API-DMAC7.html)
TW (1) TW201642864A (cg-RX-API-DMAC7.html)
WO (1) WO2016166703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013350A (es) * 2015-04-16 2018-01-25 Novartis Ag Comprimido de ribociclib.
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
AU2020336309A1 (en) 2019-08-26 2022-03-17 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
US12358920B2 (en) 2019-12-16 2025-07-15 Lunella Biotech, Inc. Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors
BR112023001454A2 (pt) * 2020-08-03 2023-02-14 Natco Pharma Ltd Composição de comprimido de liberação imediata e processo para a preparação da composição
MX2022015336A (es) * 2020-09-29 2023-01-11 Laboratorios Silanes S A De C V Combinaciones farmaceuticas de estatinas y fibratos para el tratamiento y prevencion de hiperlipidemias y enfermedades cardiovasculares.
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
AU2022311961A1 (en) 2021-07-16 2023-11-09 Dana-Farber Cancer Institute, Inc. Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
JP2025530742A (ja) 2022-08-31 2025-09-17 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質の投与計画
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20250163966A (ko) 2023-03-27 2025-11-21 노파르티스 아게 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
AU703933B2 (en) * 1994-07-12 1999-04-01 Berwind Pharmaceutical Services, Inc. Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
BRPI0917791B1 (pt) 2008-08-22 2022-03-22 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk, bem como composição farmacêutica e combinação
US8807979B2 (en) * 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
AU2011358840B2 (en) * 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
LT2872482T (lt) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
ES2676177T3 (es) * 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
AU2014233805B2 (en) * 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
MX2017013350A (es) * 2015-04-16 2018-01-25 Novartis Ag Comprimido de ribociclib.
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
CL2017002593A1 (es) 2018-05-18
EP4197530A1 (en) 2023-06-21
AU2020250190A1 (en) 2020-11-05
CA2982425A1 (en) 2016-10-20
JP2018514523A (ja) 2018-06-07
AU2022215155B2 (en) 2024-08-01
CN115554257A (zh) 2023-01-03
PE20180035A1 (es) 2018-01-09
HUE061213T2 (hu) 2023-05-28
TW201642864A (zh) 2016-12-16
BR112017021283A2 (pt) 2018-06-26
PH12017501820A1 (en) 2018-04-23
IL254818A0 (en) 2017-12-31
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
EP4620458A3 (en) 2025-10-22
KR102750931B1 (ko) 2025-01-09
HRP20230053T1 (hr) 2023-03-03
PL3283058T3 (pl) 2023-03-20
US20250134893A1 (en) 2025-05-01
US20250090531A1 (en) 2025-03-20
SI3283058T1 (sl) 2023-03-31
AR104257A1 (es) 2017-07-05
EP3283058B1 (en) 2022-11-16
CN107530292B (zh) 2022-11-01
KR20170137101A (ko) 2017-12-12
ES2938261T3 (es) 2023-04-05
US12064434B2 (en) 2024-08-20
MX2017013350A (es) 2018-01-25
SG11201708084PA (en) 2017-10-30
EP4197530B1 (en) 2025-11-12
FI3283058T3 (fi) 2023-03-01
PT3283058T (pt) 2023-02-03
CA2982425C (en) 2023-10-31
AU2016248017A1 (en) 2017-10-19
US20230104792A1 (en) 2023-04-06
EP3283058A1 (en) 2018-02-21
AU2022215155A1 (en) 2022-09-01
US20200390771A1 (en) 2020-12-17
EA201792290A1 (ru) 2018-02-28
TN2017000422A1 (en) 2019-01-16
ECSP17075052A (es) 2018-02-28
KR20250009572A (ko) 2025-01-17
AU2019201929A1 (en) 2019-04-11
CN107530292A (zh) 2018-01-02
WO2016166703A1 (en) 2016-10-20
AU2019201929B2 (en) 2020-07-09
US20250127785A1 (en) 2025-04-24
DK3283058T3 (da) 2023-02-13
EP4620458A2 (en) 2025-09-24
AU2024227794A1 (en) 2024-11-21
US10799506B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
CO2017010510A2 (es) Tableta de ribociclib
EP3652650A4 (en) TECHNIQUES FOR MANAGING ACCESS TO A HARDWARE ACCELERATOR MEMORY
BR112018013462A2 (pt) métodos de fabricação de aditivo para adesivos e artigos adesivos
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
EP2986681A4 (en) An aqueous coating composition
BR112016012615A8 (pt) sistemas, e kit
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
BR112015032445A2 (pt) componente semicondutor orgânico
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP3713436B8 (en) Face mask with moisture absorbing layer
PH12016500626A1 (en) Film coated tablet containing choline alfoscerate and process for preparing the same
EP3450435A4 (en) SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE IN POSITION 5 HAVING AN AMPK ACTIVATION ACTION
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
EP3106152A4 (en) Orally disintegrating tablet coated with film
PT3516710T (pt) Camada de barreira eletroativa limitadora da difusão para um componente optoeletrónico
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX378432B (es) Componente plàstico recubierto con una capa integrada de pvd.
EP3618837A4 (en) MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
BR112016010635A2 (pt) composto para tratamento de hipoglicemia severa
GB2543709A (en) Pharmaceutical agent
BR112017011658A2 (pt) acesso à memória por sistemas de processador duplo
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão